BerGenBio to present recent highlights from its clinical trials with selective AXL inhibitor BGB324 at DNB´s 8th Annual Nordic Healthcare Conference
(WorldNews Health)

Six ph II clinical trials ongoing with first-in-class highly selective AXL inhibitor BGB324. Monotherapy data at 19% RR in relapsed/refractory AML and MDS reported at ASH. 50% CBR with BGB324 in combination with erlotinib reported at World Lung. BGB324 in combination with docetaxel as last line therapy in NSCLC showing very promising early efficacy at 66% CBR. Bergen, Norway, 14 December 2017 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the Company will be presenting recent clinical highlights at the DNB`s 8th Annual Nordic Healthcare Conference in Oslo, Norway, today...